Combination treatment for borderline resectable pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new treatment approach for pancreatic cancer that is on the edge of being removable with surgery. It combines radiation therapy with chemotherapy and an immunotherapy drug (a PD-1 inhibitor) plus a thymalfasin (a medication that helps regulate the immune system) to see if this combination can help shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and in generally good physical condition (able to care for yourself).
- You must have a confirmed diagnosis of pancreatic cancer that is borderline resectable, meaning it is on the edge of being removable with surgery.
- You must not have had any prior chemotherapy, immunotherapy, or other systemic treatment for this cancer.
- Your blood tests must show adequate bone marrow and liver/kidney function (e.g., enough white blood cells, red blood cells, and platelets).
- You must not have active infections like HIV, hepatitis B or C, or tuberculosis, and you must not have an autoimmune disease.
- You must agree to use birth control during the study if you are of childbearing potential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy regimens (AG and FOLFIRINOX) with an immunotherapy drug (a PD-L1 antibody) before surgery for pancreatic cancer that is borderline resectable or locally advanced. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
This trial tests a new combination of drugs with radiation therapy for people with locally advanced pancreatic cancer that cannot be removed with surgery. The treatment aims to shrink the tumor and improve outcomes.
This study tests a new drug (IBI343) combined with chemotherapy given before surgery for pancreatic cancer that is borderline resectable. The goal is to shrink the tumor enough so it can be removed with surgery, and this treatment focuses on a specific marker on cancer cells.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Hear when a new Carcinoma, Pancreatic Ductal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.